Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRas wild-type tumors

Journal of Thoracic Oncology

Volumn 10, Issue 2, 2015, Pages 392-396

  Toffalorio, Francesca ^a   De Marinis, Filippo ^a   Conforti, Fabio ^a   Spitaleri, Gianluca ^a   Catania, Chiara ^a   Noberasco, Cristina ^a   Lazzari, Chiara ^a   Vecchio, Fabio ^a   Stufano, Viviana ^a   Barberis, Massimo ^a   De Pas, Tommaso ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Chromosome 7 high polysomy; Epidermal growth factors tyrosine wild type; Erlotinib

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; K RAS PROTEIN; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; QUINAZOLINE DERIVATIVE; RAS PROTEIN; TUMOR MARKER;

ARTICLE; CANCER PATIENT; CHROMOSOME 7; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SMOKING; TREATMENT RESPONSE; WILD TYPE; ANEUPLOIDY; CARCINOMA, NON-SMALL-CELL LUNG; COHORT ANALYSIS; DISEASE FREE SURVIVAL; GENETICS; LUNG NEOPLASMS; ONCOGENE RAS; PATHOLOGY; PROGNOSIS;

ANEUPLOIDY; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOMES, HUMAN, PAIR 7; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84922239775     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000355     Document Type: Article

References (12)

1. Mok TS, Thongprasert S, Yang CH, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957
2. Yang CH, Yu CJ, Shih JY, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive nonsmall-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008;26:2745-2753
3. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-2501
4. Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 2007;13:4954-4955
5. Hirsch FR, Varella-Garcia M, McCoy J, et al; Southwest Oncology Group. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005;23:6838-6845
6. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-655
7. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24: 5034-5042
8. Hirsch FR, Varella-Garcia M, Cappuzzo F, et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007;18:752-760
9. Garassino MC, Martelli O, Broggini M, et al; TAILOR Trialists. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013;14:981-988
10. Gregorc V, Novello S, Lazzari C, et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. Lancet Oncol 2014;15:713-721
11. Dahabreh IJ, Linardou H, Kosmidis P, Bafaloukos D, Murray S. EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer. Ann Oncol 2011;22:545-552
12. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, firstline study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-2874